Biotech Startups
9,920 companies tagged Biotech, with their investors and founders.
2 investors
Cleveland HeartLab is a clinical laboratory company, part of Quest Diagnostics, focused on cardiovascular disease testing and diagnostics.
2 investors
ClostraBio develops next-generation probiotics and a platform for delivering bacterial metabolites to support gut health, targeting inflammatory bowel disease (IBD) and food allergy. Its lead product, CLB101 (Anaerostipes caccae), is a probiotic aimed at supporting gut barrier function, immunity, and microbiome balance, offered both as a dietary supplement and a therapeutic delivery platform.
2 investors
Calira (Clustermarket) provides lab equipment booking and management software that lets LabOps teams schedule shared scientific instruments, track utilisation and maintenance, and build a searchable equipment directory across one or many labs. It generates structured usage data that can be exported and integrated with ELN, AI, or BI platforms to support CapEx planning and reduce downtime.
2 investors
2 investors
Coagulant Therapeutics is a biopharmaceutical company, formed in 2019, developing biologics with a focus on hematology and coagulation-related therapeutics.
2 investors
CoBX Bio is a drug discovery company working in chemical proteomics. The available page content is limited to legal notices and a tagline, offering little detail about specific programs or products.
2 investors
Codagenix develops viral vaccines and virotherapeutics using codon deoptimization, a method for engineering attenuated viruses. The company applies this platform in clinical development, drawing on expertise in virology, computational science, and patient care.
2 investors
Codetta Bio develops multiplex biomarker detection technology that combines digital PCR, real-time PCR, and immunoPCR with microbead-based target capture to simultaneously measure proteins, DNA, and RNA from a single sample. Its tools serve multi-omics research and life sciences applications.
2 investors
Cambridge, MA clinical-stage biotech developing engineered exosome therapeutics; IPO'd on NASDAQ in 2020, later restructured.
2 investors
Coegin Pharma develops and commercializes advanced cosmetic peptide technologies for hair and skin care, targeting the global longevity and wellness market. The company's flagship product, Follicopeptide®, addresses hair thinning, while a second innovation, NPP-4, targets skin tone enhancement.
2 investors
Cognito Therapeutics develops Spectris, a non-invasive sensory stimulation technology platform to treat neurodegenerative diseases including Alzheimer's by improving cognitive performance. The company serves patients with neurodegenerative conditions and aims to transform disease management through clinical-to-commercial pathways in the neurological therapeutics sector.
2 investors
Colospan develops the CG-100, an internal bypass medical device for colorectal surgery that provides an alternative to stoma pouches. The company serves surgeons and patients requiring colorectal procedures in the medtech sector.
2 investors
Combat is a clinical-stage cancer treatment company focused on developing therapies for bladder and prostate cancer. The company is advised by leading urologic surgeons and oncologists specializing in robotic surgery and immunotherapy approaches.
2 investors
Complement Therapeutics is a clinical-stage biotechnology company developing gene therapies for complement-mediated diseases, with a lead AAV-based candidate (CTx001) for Geographic Atrophy secondary to Age-related Macular Degeneration. A University of Manchester spinout, it runs clinical and natural history studies in ophthalmology across the US and UK.
2 investors
Complix develops therapeutic biologics based on Alphabody technology targeting viral diseases, oncology, and autoimmune conditions. The company focuses on cell-penetrating therapeutics designed to reach intracellular disease targets.
2 investors
Concentric AG produces microbial biological crop inputs that enhance plant vigor, soil health, and harvest yield while helping plants resist environmental stress and disease. The products are designed for growers in conventional agriculture and organic production, compatible with standard farming practices from field crops to greenhouse and hydroponic systems.
2 investors
Confluence Pharma is a clinical-stage biopharmaceutical company developing sustained-release drug formulations to treat the core social and communication impairments of Fragile X Syndrome, Autism, and other neurodevelopmental, neuropsychiatric, and addiction-related disorders. Its treatments target pediatric and adult patients, addressing symptoms such as communication, social behavior, attention, anxiety, and hyperactivity.
2 investors
Connect Biopharma is a clinical-stage biopharmaceutical company developing antibody-based therapies targeting inflammatory diseases such as atopic dermatitis and asthma. The company operates globally with headquarters in San Diego and operations in the U.S. and China.
2 investors
Context Therapeutics develops clinical-stage T cell engaging bispecific antibody therapies for the treatment of solid tumors. Its pipeline targets antigens such as Claudin 6, mesothelin, and Nectin-4 to direct the immune system against difficult-to-treat cancers.
2 investors
Converge Bio develops generative AI models trained on DNA, RNA, and protein sequences to support drug discovery and development for biotech and pharmaceutical companies. The company provides AI solutions for target discovery, antibody design, protein manufacturing optimization, and biomarker discovery.
2 investors
Convoke offers an AI platform that ingests and structures data from documents, scientific literature, SEC filings, and clinical data, and deploys custom agents to automate knowledge tasks and generate reports, manuscripts, and landscape analyses. It is built for biopharma teams working in competitive intelligence, medical affairs, portfolio strategy, and business development.
2 investors
Corcept develops cortisol modulators — molecules that regulate cortisol activity at the glucocorticoid receptor — to treat serious diseases across endocrinology, oncology, metabolism, and neurology. Its FDA-approved drug Korlym (mifepristone) treats hypercortisolism (Cushing syndrome), and the company has over 30 ongoing studies and more than 1,000 discovered proprietary cortisol modulators.
2 investors
CORE Biomedicine is a biotech company developing precision cancer medicines based on cancer lineage biology, focused on advancing drug candidates from discovery into clinical development.
2 investors